<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>anti-osteoporosis medications &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/anti-osteoporosis-medications/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 05 Oct 2026 14:00:38 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>anti-osteoporosis medications &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Parkinson&#8217;s Doubles Hip Fracture Risk, Yet Osteoporosis Drugs Are No More Likely After Breaks</title>
		<link>https://bioengineer.org/parkinsons-doubles-hip-fracture-risk-yet-osteoporosis-drugs-are-no-more-likely-after-breaks/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 05 Oct 2026 14:00:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[anti-osteoporosis medications]]></category>
		<category><![CDATA[Bisphosphonates]]></category>
		<category><![CDATA[Bone Health]]></category>
		<category><![CDATA[denosumab]]></category>
		<category><![CDATA[fall risk]]></category>
		<category><![CDATA[Finland]]></category>
		<category><![CDATA[fracture prevention]]></category>
		<category><![CDATA[hip fracture]]></category>
		<category><![CDATA[nationwide cohort]]></category>
		<category><![CDATA[osteoporosis]]></category>
		<category><![CDATA[Parkinson’s disease]]></category>
		<category><![CDATA[secondary prevention]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=402628</guid>

					<description><![CDATA[A nationwide Finnish cohort study found that people with Parkinson's disease receive anti-osteoporosis medications at rates similar to or higher than matched controls, yet only about one in five patients of either group receives bone-protecting drugs after a hip fracture, suggesting fall-prevention strategies are urgently needed alongside pharmacotherapy.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">402628</post-id>	</item>
	</channel>
</rss>
